BMS-210285
BMS-210285 is a highly selective agonist for the 3 receptor. BMS-210285 has a Ki of 9 nM at the human 3-adrenoceptor. BMS-210285 possesses a 3 intrinsic activity of 83% relative to isoproterenol. BMS-210285 can be studied for obesity and type 2 diabetes research.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 344607-69-8
- Fòrmula: C24H25ClF2N2O5S
- Peso molecular:526.98
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Ver todos los productos específicos de isoformas Adrenergic Receptor
More
Actividad biológica
Descripciòn
Chemical Information
-
No. CAS 344607-69-8
-
Peso molecular 526.98
-
Fòrmula C24H25ClF2N2O5S
-
SMILES
CS(=O)(NC1=CC([C@@H](O)CN[C@@H](C2=CC=C(OC(F)F)C=C2)CC3=CC=CC(Cl)=C3)=CC=C1O)=O
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocolo
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
Pureza y Documentación
Referencias
[1]. Hu, B., & Jennings, L. L. (2003). Orally bioavailable beta 3-adrenergic receptor agonists as potential therapeutic agents for obesity and type-II diabetes. Progress in medicinal chemistry, 41, 167-194. [Content Brief]
[2]. Kordik, C. P., & Reitz, A. B. (1999). Pharmacological treatment of obesity: therapeutic strategies. Journal of medicinal chemistry, 42(2), 181-201. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)